- Home
- RCMT vs NGEN Comparison
RCMT vs NGEN Comparison
Compare RCMT & NGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RCMT | NGEN |
|---|---|---|
| Founded | 1971 | 2017 |
| Country | United States | Canada |
| Employees | N/A | 9 |
| Industry | Professional Services | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 196.0M | 175.1M |
| IPO Year | 1997 | N/A |
Fundamental Metrics
Financial Performance| Metric | RCMT | NGEN |
|---|---|---|
| Price | $22.00 | $2.06 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $36.00 | $18.00 |
| AVG Volume (30 Days) | 72.9K | ★ 1.0M |
| Earning Date | 04-03-2026 | 04-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 27.38 | N/A |
| EPS | ★ 0.52 | N/A |
| Revenue | ★ $186,737,000.00 | N/A |
| Revenue This Year | $11.89 | N/A |
| Revenue Next Year | $12.46 | N/A |
| P/E Ratio | $41.15 | ★ N/A |
| Revenue Growth | ★ 5.83 | N/A |
| 52 Week Low | $17.26 | $1.98 |
| 52 Week High | $32.50 | $5.93 |
Technical Indicators
Market Signals| Indicator | RCMT | NGEN |
|---|---|---|
| Relative Strength Index (RSI) | 32.23 | 22.42 |
| Support Level | $21.11 | N/A |
| Resistance Level | $25.31 | $4.52 |
| Average True Range (ATR) | 1.43 | 0.17 |
| MACD | -0.65 | -0.18 |
| Stochastic Oscillator | 12.14 | 3.96 |
Price Performance
Historical ComparisonAbout RCMT RCM Technologies Inc.
RCM Technologies Inc is a provider of business and technology solutions designed to enhance and maximize the operational performance of its customers. It operates in three segments: Specialty Health Care, Engineering, and Life Sciences, Data and Solutions (LS&D). The company generates maximum revenue from the Specialty Health Care segment that provides staffing solutions including medical healthcare professionals, health information management professionals, nurses, paraprofessionals, physicians, and therapists. Geographically, it derives a majority of its revenue from the United States and also has a presence in Canada, Puerto Rico, the Philippines, and Europe.
About NGEN NervGen Pharma Corp. Common stock
NervGen Pharma Corp is a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury and other traumatic and neurologic conditions. The Company's principal business activity is the discovery, development and commercialization of neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions. NervGen's initial target indication is SCI. The company's pipeline products include NVG-291 and NVG-300.